Eyetech Pharmaceuticals set a price of $995 per injection for Macugen, a new drug to treat wet age-related macular degeneration, the leading cause of blindness in the elderly. The drug is to be injected about nine times a year, bringing the total cost to $9,000. Eyetech and its partner, Pfizer, plan to begin selling the drug early next year.

Full Story:

Related Summaries